
DISCO Pharmaceuticals gets $40M upfront from AbbVie and could earn up to $2.5B in milestones to develop AND-gated bispecifics for solid tumors.
Pharma leaders (and Pharm Exec readers) reflect on the ideas and events that revolutionized the industry over the last quarter of a century--and what to watch for in the next 25.
over 20 years ago
Time Machineover 20 years ago
Getting Betterover 20 years ago
States Curb Marketingover 20 years ago
From the Editor: Take Your Seatover 20 years ago
Quiz Answersover 20 years ago
Introduction: Pharm Exec at 25over 20 years ago
How Far We've Come





